Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors

#452

Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.

Aim(s): We describe an international validation study designed to assess the clinical and psychometric reliability, validity and responsiveness-to-change of the QLQ-GINET21 in patients with NETs.

Materials and methods: Two-hundred and fifty patients were recruited into this international multicenter study. The sites of NET included any gut or lung primary with metastases, or a pancreatic primary. The study required that all patients complete two HRQoL questionnaires – the EORTC QLQ-C30 (version 3.0) and the QLQ-GINET21 – at all assessment time points. Each was studied in two groups: Group 1 (somatostatin [SMS] analogues and Interferon) and Group 2 (all other treatments).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ramage J, Yadegarfar G, Friend L, Jones L, Plum L,

Keywords: Quality of Life, PROMS,